|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Dartmouth-Hitchcock Medical Center |
|---|---|
| Collaborator: |
National Institutes of Health (NIH) |
| Information provided by (Responsible Party): | Dartmouth-Hitchcock Medical Center |
| ClinicalTrials.gov Identifier: | NCT00453921 |
Purpose
Traumatic brain injury (TBI) is a significant public health problem, with 1.5-2.0 million Americans injured each year. Cognitive deficits, particularly in the domains of memory and attention are frequently the source of lingering disability after TBI and a source of enormous distress to the injured individuals and their family/caregivers. To date, interventions to ameliorate chronic cognitive deficits have been directed at either pharmacological interventions or cognitive rehabilitation. We propose to (1) To compare the efficacy of three interventions: memory and attention training (MAAT), methylphenidate, and memory/attention training in combination with methylphenidate and (2) use functional MRI (fMRI) to characterize changes in activation of the neural circuitry of memory and attention due to MAAT alone, methylphenidate alone, and MAAT in combination with methylphenidate. This is a two by two design with medication (methylphenidate/placebo) and cognitive therapy (Memory and Attention Training (MAAT) or an Attention control intervention) as possible interventions. Using a randomized, placebo-controlled, double-blind design, 200 individuals with persistent cognitive deficits 6-12 months after MTBI will be randomized to receive a six week trial of either (1) MAAT and placebo, (2) MAAT and methylphenidate (0.3 mg/kg BID), (3) attention control intervention and methylphenidate (0.3 mg/kg BID), or (4) attention control intervention and placebo. Symptom distress, attention and memory performance, and activation patterns of the neural circuitry of attention and memory while undergoing fMRI will be characterized at baseline, and after the four treatment conditions. This study will provide important information on three interventions for the most disabling sequelae of an enormous public health problem. Further, it will help to clarify underlying neural mechanisms and suggest additional treatment possibilities.
| Condition | Intervention |
|---|---|
|
Brain Injury |
Drug: Methylphenidate Behavioral: Memory and Attention Training Other: Placebo as both treatments |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Factorial Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI) |
| Estimated Enrollment: | 160 |
| Study Start Date: | February 2007 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: 1
Placebo Capsule and Placebo Memory and Attention Training
|
Other: Placebo as both treatments
Placebo capsules and Placebo Memory and Attention Training
|
|
Active Comparator: 2
Methylphenidate capsules and Memory and Attention Training
|
Drug: Methylphenidate
Dosage dependent on weight
Behavioral: Memory and Attention Training
Weekly Memory and Attention Training with at home practice.
|
|
Active Comparator: 3
Methylphenidate capsules and Placebo Memory and Attention Training
|
Drug: Methylphenidate
Dosage dependent on weight
|
|
Active Comparator: 4
Placebo capsules and Memory and Attention Training
|
Behavioral: Memory and Attention Training
Weekly Memory and Attention Training with at home practice.
|
Summary and Gaps to be Addressed by the Proposed Study
What is known: There are two interventions of promising efficacy in ameliorating deficits in attention and memory after MTBI: (i) memory and attention training/rehabilitation, and (ii) catecholaminergic augmentation (particularly with methylphenidate - which augments both dopaminergic and adrenergic systems). fMRI and other functional imaging strategies are providing valuable insights into the underlying neural mechanisms of the cognitive enhancing effects of methylphenidate in some neuropsychiatric populations (individuals with ADHD), and the effects of cognitive rehabilitation efforts in some domains (e.g. speech and language in individuals after stroke).
What is not known: To date there are no studies that apply a psychopharmacological strategy of augmenting neurotransmitter systems known to modulate memory/attention (dopaminergic and adrenergic systems) in combination with a cognitive rehabilitation intervention known to improve memory/attention (memory/attention training) in individuals with MTBI. We are aware of no published studies that use fMRI to assess the neural mechanisms of memory/attention improvement from the use of catecholaminergic agents or memory/attention training in individuals with MTBI. It is important to determine the efficacy of combined memory/attention training and methylphenidate. It is equally important to begin to understand the neural mechanisms underlying effective treatment as it may help to inform the development of the next generation of interventions and perhaps lead to individually tailored treatment interventions. This proposal will start to address these gaps in our knowledge.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
The following factors will exclude otherwise eligible subjects from participation:
Contacts and Locations| Contact: Marcia Davis, M.Ed., CAGS | 603-650-2670 | Marcia.Davis@hitchcock.org |
| Contact: Heather S Pixley, MBA | 603-650-5037 | Heather.S.Pixley@hitchcock.org |
| United States, Colorado | |
| University of Colorado at Denver | Recruiting |
| Denver, Colorado, United States, 80291-0238 | |
| Contact: Kimberly Frey, MS, CCC-SLP 303-724-4990 Kim.Frey@ucdenver.edu | |
| Contact: Jody Newman, MA, CCC-SLP (303) 349-1887 Jody.Newman@ucdenver.edu | |
| Principal Investigator: David Arciniegas, MD | |
| United States, Indiana | |
| Indiana University | Recruiting |
| Indianapolis, Indiana, United States, 46266-6057 | |
| Contact: Kim Campbell, MSW 317-274-6633 kimacamp@iupui.edu | |
| Contact: Brenna C. McDonald, PsyD, MBA (317) 278-8878 mcdonalb@iupui.edu | |
| Principal Investigator: Brenna C. McDonald, PsyD, MBA | |
| United States, New Hampshire | |
| Dartmouth-Hitchcock Medical Center | Recruiting |
| Lebanon, New Hampshire, United States, 03756 | |
| Contact: Marcia A. Davis, M.Ed., CAGS 603-650-2670 Marcia.Davis@hitchcock.org | |
| Contact: Mary Jo Manley, Ed.D. (603) 650-5824 Mary.Jo.Manley@dartmouth.edu | |
| Principal Investigator: Thomas W McAllister, MD | |
| Principal Investigator: | Thomas W McAllister, MD | Dartmouth-Hitchcock Medical Center, Dartmouth Medical School |
More Information
| Responsible Party: | Dartmouth-Hitchcock Medical Center |
| ClinicalTrials.gov Identifier: | NCT00453921 History of Changes |
| Other Study ID Numbers: | 17363, 5R01HD47242 |
| Study First Received: | March 27, 2007 |
| Last Updated: | October 19, 2011 |
| Health Authority: | United States: Institutional Review Board |
|
TBI Memory Methylphenidate Ritalin Memory and Attention Training |
|
Brain Injuries Brain Diseases Central Nervous System Diseases Nervous System Diseases Craniocerebral Trauma Trauma, Nervous System Wounds and Injuries Methylphenidate Dopamine Uptake Inhibitors |
Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Neurotransmitter Uptake Inhibitors Physiological Effects of Drugs Central Nervous System Stimulants Central Nervous System Agents Therapeutic Uses |